Companion Animals

Dog Canine Immunotherapy Biologics Welfare

Biologic therapies targeting specific immune pathways have transformed management of inflammatory and immune-mediated conditions in dogs.

Key Facts

Lokivetmab, a monoclonal antibody targeting IL-31, provides rapid itch relief in atopic dermatitis
Oclacitinib, a JAK inhibitor, reduces itch and inflammation with a different mechanism of action
Biologic therapies have fewer organ-system side effects than long-term steroid treatment
High cost limits access for some owners, creating welfare inequality in treatment access
Novel biologics targeting IL-4, IL-13, and IL-33 are in development for canine atopy

Welfare Considerations

Dogs receiving targeted biologic therapies achieve superior itch control with fewer side effects than traditional immunosuppressants. These treatments represent a major welfare advance for chronically itchy dogs when access is not limited by cost.

What You Can Do

Discuss biologic therapy options with a veterinary dermatologist for dogs with severe atopic dermatitis
Advocate for affordable access to biologic veterinary medicines
Support development of cost-effective generic biologic therapies for companion animal conditions